stoxline Quote Chart Rank Option Currency Glossary
  
NeuroSense Therapeutics Ltd. (NRSN)
0.6225  -0.138 (-17.73%)    07-19 13:55
Open: 0.761
High: 0.7911
Volume: 878,705
  
Pre. Close: 0.7602
Low: 0.5136
Market Cap: 11(M)
Technical analysis
2024-07-19 1:21:50 PM
Short term     
Mid term     
Targets 6-month :  1.34 1-year :  1.75
Resists First :  1.15 Second :  1.5
Pivot price 1
Supports First :  0.58 Second :  0.49
MAs MA(5) :  0.78 MA(20) :  0.97
MA(100) :  1.34 MA(250) :  1.05
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  6.4 D(3) :  13.6
RSI RSI(14): 29.1
52-week High :  2.32 Low :  0.4
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NRSN ] has closed below the lower bollinger band by 3.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ NRSN ] is to continue within current trading range. Bollinger Bands are 32.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.78 - 0.79 0.79 - 0.79
Low: 0.69 - 0.69 0.69 - 0.7
Close: 0.75 - 0.76 0.76 - 0.77
Company Description

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Headline News

Fri, 12 Jul 2024
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Update - Defense World

Tue, 09 Jul 2024
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression - PR Newswire

Wed, 03 Jul 2024
NeuroSense Shareholders Approve Key Resolutions - TipRanks

Mon, 01 Jul 2024
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug - PR Newswire

Mon, 24 Jun 2024
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results - PR Newswire

Fri, 21 Jun 2024
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 18 (M)
Shares Float 11 (M)
Held by Insiders 27.4 (%)
Held by Institutions 1.1 (%)
Shares Short 8 (K)
Shares Short P.Month 21 (K)
Stock Financials
EPS -0.94
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.45
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -222.2 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.67
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.65
PEG Ratio 0
Price to Book value -1.33
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android